Methylenetetrahydrofolate reductase C677T gene mutation and hyperhomocysteinemia in Budd-Chiari syndrome and portal vein thrombosis: A systematic review and meta-analysis of observational studies

Hepatology Research

Volumn 44, Issue 14, 2014, Pages E480-E498

  Qi, Xingshun ^a,b   Yang, Zhiping ^a   De Stefano, Valerio ^c   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b The 463 Hospital of Chinese PLA   (China)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

Budd Chiari syndrome; Homocysteine; Meta analysis; Methylenetetrahydrofolate reductase C677T mutation; Portal vein thrombosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE;

ARTICLE; BUDD CHIARI SYNDROME; C677T GENE; COHORT ANALYSIS; COMPARATIVE STUDY; GENE; GENE MUTATION; GENETIC ASSOCIATION; HOMOZYGOTE; HUMAN; HYPERHOMOCYSTEINEMIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; META ANALYSIS; OBSERVATIONAL STUDY; PORTAL VEIN THROMBOSIS; PREVALENCE; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

EID: 84918572388     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12348     Document Type: Article

References (68)

1. Key NS, McGlennen RC. Hyperhomocyst(e)inemia and Thrombophilia. Arch Pathol Lab Med 2002; 126: 1367-1375.
2. Miner SE, Evrovski J, Cole DE. Clinical chemistry and molecular biology of homocysteine metabolism: an update. Clin Biochem 1997; 30: 189-201.
3. Medina MA, Amores-Sanchez MI. Genetic basis of hyperhomocysteinemia. Mol Genet Metab 2000; 71: 478-480.
4. Frosst P, Blom HJ, Milos R etal. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
5. Clarke R, Daly L, Robinson K etal. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-1155.
6. den Heijer M, Koster T, Blom HJ etal. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-762.
7. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998; 158: 2101-2106.
8. Margaglione M, D'Andrea G, d'Addedda M etal. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV Leiden and the prothrombin A20210 mutation. Thromb Haemost 1998; 79: 907-911.
9. Gemmati D, Serino ML, Trivellato C, Fiorini S, Scapoli GL. C677T substitution in the methylenetetrahydrofolate reductase gene as a risk factor for venous thrombosis and arterial disease in selected patients. Haematologica 1999; 84: 824-828.
10. DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology 2009; 49: 1729-1764.
11. Senzolo M, Riggio O, Primignani M. Vascular disorders of the liver: recommendations from the Italian Association for the Study of the Liver (AISF) ad hoc committee. Dig Liver Dis 2011; 43: 503-514.
12. Hoekstra J, Janssen HL. Vascular liver disorders (I): diagnosis, treatment and prognosis of Budd-Chiari syndrome. Neth J Med 2008; 66: 334-339.
13. Hoekstra J, Janssen HL. Vascular liver disorders (II): portal vein thrombosis. Neth J Med 2009; 67: 46-53.
14. Stroup DF, Berlin JA, Morton SC etal. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012.
15. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
18. AISF Annual Meeting abstracts (16/18 February 2005). Dig Liver Dis 2005; 37: A31-A53.
19. D'Amico M, Niceta M, Sammarco P, Virdone R, Sinagra E. Pivot role of PAI 1 4G4G in non-cirrhotic portal vein thrombosis and Budd-Chiari syndrome. J Hepatol 2011; 54: S355.
20. Hoekstra J, Casellas-Caro M, Garcia-Pagan JC etal. Etiologic factors underlying Budd-Chiari syndrome and portal vein thrombosis: the role of site-specific thrombosis. Hepatology 2010; 52: 896A.
21. Koliou P, Kouvelos G, Mitsis M etal. IS the double compound heterozygosity of hemoglobin s/bthalassemia a risk factor for abdominal venous thrombosis? Haematologica 2010; 95: 763-764.
22. Alkim H, Ayaz S, Parlak E, Sasmaz N. Homocysteine is not an important factor in liver disorders related with thrombosis. Hepatol Int 2012; 6: 307-308.
23. D'Amico M, Niceta M, Sammarco P, Virdone R, Sinagra E. 891 pivot role of pai 1 4G4G in non-cirrhotic portal vein thrombosis and Budd-Chiari syndrome. J Hepatol 2011; 54 (Suppl 1): S355.
24. Luciani M, Pietrobattista A, Abraldes JG etal. Influence of genetic thrombophilic disorders in extrahepatic portal vein thrombosis in children and adolescents. J Thromb Haemost 2011; 9: 179.
25. Mattson J, Zhuang Y, Crisan D. JAK2 gene mutation in patients with abdominal venous thrombosis. Int J Lab Hematol 2011; 33: 107.
26. Shah SR, DasGupta A, Sharma A etal. Thrombophilic conditions in non-cirrhotic portal vein thrombosis. Indian J Gastroenterol 2005; 24: 205-210.
27. Madonna P, de Stefano V, Coppola A, Cerbone AM, di Minno G. G20210A prothrombin gene mutation and other trombophilic polymorphisms in patients with portal or hepatic venous thrombosis. Gastroenterology 2001; 120: 1059-1060.
28. Pasta L, Marrone C, D'Amico M etal. MTHFR C677T homozygous as risk factor for complications after OLT for cryptogenic cirrhosis. Clin Transplant 2006; 20: 796-798.
29. Amitrano L, Brancaccio V, Guardascione MA etal. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology 2000; 31: 345-348.
30. Amitrano L, Brancaccio V, Guardascione MA etal. Portal vein thrombosis after variceal endoscopic sclerotherapy in cirrhotic patients: role of genetic thrombophilia. Endoscopy 2002; 34: 535-538.
31. Amitrano L, Anna Guardascione M, Brancaccio V etal. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004; 40: 736-741.
32. Buchel O, Roskams T, Van Damme B, Nevens F, Pirenne J, Fevery J. Nodular regenerative hyperplasia, portal vein thrombosis, and avascular hip necrosis due to hyperhomocysteinaemia. Gut 2005; 54: 1021-1023.
33. 660 Cryptogenic liver cirrhosis (CLC) with portal vein thrombosis (PVT): role of MTHFR C677T mutation. J Hepatol 2005; 42 (Suppl 2): 241.
34. Amitrano L, Guardascione MA, Brancaccio V etal. Inherited trombophilic disorders in patients with portal vein thrombosis. J Hepatol 2000; 32 (Suppl 2): 133.
35. Bhattacharyya M, Makharia G, Kannan M, Ahmed RP, Gupta PK, Saxena R. Inherited prothrombotic defects in Budd-Chiari syndrome and portal vein thrombosis: a study from North India. Am J Clin Pathol 2004; 121: 844-847.
36. Chamouar P, Voegeli A-C, Pencreach E etal. Coexistence of the methylene tetrahydrofolate reductase (MTHFR) Cs77T, the factor II G20210A and the factor V Leiden mutations in idiopathic portal vein thrombosis. Gastroenterology 2001; 120: A196.
37. D'Amico M, Pasta L, Sammarco P. MTHFR C677TT, PAI1 4G-4G, V Leiden Q506, and prothrombin G20210A in hepatocellular carcinoma with and without portal vein thrombosis. J Thromb Thrombolysis 2009; 28: 70-73.
38. Erkan O, Bozdayi AM, Disibeyaz S etal. Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis. Eur J Gastroenterol Hepatol 2005; 17: 339-343.
39. Gabr MA, Bessa SS, El-Zamarani EA. Portal vein thrombosis in Egyptian patients with liver cirrhosis: role of methylenetetrahydrofolate reductase C677T gene mutation. Hepatol Res 2010; 40: 486-493.
40. Heller C, Schobess R, Kurnik K etal. Abdominal venous thrombosis in neonates and infants: role of prothrombotic risk factors - a multicentre case-control study. For the Childhood Thrombophilia Study Group. Br J Haematol 2000; 111: 534-539.
41. Li XM, Wei YF, Hao HL etal. Hyperhomocysteinemia and the MTHFR C677T mutation in Budd-Chiari syndrome. Am J Hematol 2002; 71: 11-14.
42. Mangia A, Villani MR, Cappucci G etal. Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors. Eur J Gastroenterol Hepatol 2005; 17: 745-751.
43. Pasta L, Marrone C, D'Amico M etal. MTHFR C677T mutations in liver cirrhosis with and without portal vein thrombosis. Liver Int 2006; 26: 269-270.
44. Pellicelli AM, D'Ambrosio C, Barbaro G etal. 180 clinical and genetic factors associated to development of portal vein thrombosis in cirrhotic patients without hepatocellular carcinoma. J Hepatol 2011; 54 (Suppl 1): S77.
45. Pinto RB, Silveira TR, Bandinelli E, Rohsig L. Portal vein thrombosis in children and adolescents: the low prevalence of hereditary thrombophilic disorders. J Pediatr Surg 2004; 39: 1356-1361.
46. Salama K, El-Koofy N, El-Hawary M etal. Thrombophilic factors in Egyptian children with portal vein thrombosis. Indian J Gastroenterol 2007; 26: 252-253.
47. Vaya A, Plume G, Bonet E, Carrasco P, Morales-Suarez-Varela MM. Hyperhomocysteinemia and the methylene tetrahydrofolate reductase C677T mutation in splanchnic vein thrombosis. Eur J Haematol 2011; 86: 167-172.
48. Colak Y, Karasu Z, Oruc N etal. Hyperhomocysteinaemia and factor V Leiden mutation are associated with Budd-Chiari syndrome. Eur J Gastroenterol Hepatol 2006; 18: 917-920.
49. Maras JS, Garg V, Sarin SK. MTHFR C677T, prothrombin G20210A and JAK2 V617F mutations are associated with increased risk of portal vein thrombosis in patients with chronic liver disease. Hepatology 2010; 52: 904A.
50. Tian H, Xu H, Zu MH, Pei DS. Correlation of MTHFR C677T gene polymorphism plasma and Hcy levels in young patients with hepatic vein obstruction. J Interv Radiol 2012; 21: 62-65.
51. Dentali F, Squizzato A, Brivio L etal. JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 2009; 113: 5617-5623.
52. Qi X, Yang Z, Bai M, Shi X, Han G, Fan D. Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis. Aliment Pharmacol Ther 2011; 33: 1087-1103.
53. Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 2012; 120: 4921-4928.
54. Dentali F, Galli M, Gianni M, Ageno W. Inherited thrombophilic abnormalities and risk of portal vein thrombosis. a meta-analysis. Thromb Haemost 2008; 99: 675-682.
55. Qi X, De Stefano V, Wang J etal. Prevalence of inherited antithrombin, protein C, and protein S deficiencies in portal vein system thrombosis and Budd-Chiari syndrome: a systematic review and meta-analysis of observational studies. J Gastroenterol Hepatol 2013; 28: 432-442.
56. Qi X, Chen H, Han G. Effect of antithrombin, protein C and protein S on portal vein thrombosis in liver cirrhosis: a meta-analysis. Am J Med Sci 2013; 346: 38-44.
57. Ray JG, Shmorgun D, Chan WS. Common C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of venous thromboembolism: meta-analysis of 31 studies. Pathophysiol Haemost Thromb 2002; 32: 51-58.
58. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005; 3: 292-299.
59. Northup PG, McMahon MM, Ruhl AP etal. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006; 101: 1524-1528.
60. Sogaard KK, Horvath-Puho E, Gronbaek H, Jepsen P, Vilstrup H, Sorensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol 2009; 104: 96-101.
61. Wu H, Nguyen GC. Liver cirrhosis is associated with venous thromboembolism among hospitalized patients in a nationwide US study. Clin Gastroenterol Hepatol 2010; 8: 800-805.
62. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365: 147-156.
63. Tripodi A, Primignani M, Chantarangkul V etal. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009; 137: 2105-2111.
64. Bosy-Westphal A, Petersen S, Hinrichsen H, Czech N, J Müller M. Increased plasma homocysteine in liver cirrhosis. Hepatol Res 2001; 20: 28-38.
65. Zhou XM, Lin JS, Sun XM etal. The relationship between the plasma homocysteine level and the polymorphism of MTHFR gene C667T in liver cirrhosis. Zhonghua Gan Zang Bing Za Zhi 2005; 13: 908-910.
66. Halifeoglu I, Gur B, Aydin S, Ozturk A. Plasma trace elements, vitamin B12, folate, and homocysteine levels in cirrhotic patients compared to healthy controls. Biochemistry Mosc 2004; 69: 693-696.
67. Qi X, Wu F, Ren W etal. Thrombotic risk factors in Chinese Budd-Chiari syndrome patients. An observational study with a systematic review of the literature. Thromb Haemost 2013; 109: 878-884.
68. Quinlivan EP, Gregory JF, 3rd. Effect of food fortification on folic acid intake in the United States. Am J Clin Nutr 2003; 77: 221-225.